Pfizer’s shares dropped steeply on Tuesday as global markets trended upward. Analysts lowered estimates for the firm over a thin pipeline. Some investors remain concerned the pipeline looks thin and leadership remains unsettled.
But Pfizer won a key approval: the first CDK4/6 maintenance therapy for advanced HER2-positive breast cancer. Yet, the stock losses eclipsed the good news. Offices in Midtown Manhattan evacuated after beams buckled, sparking collapse concerns.